New vaccine combo aims to stop myeloma before it starts
NCT ID NCT02886065
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 32 times
Summary
This early-phase study tests a cancer vaccine (PVX-410) together with two other drugs (citarinostat and lenalidomide) in 19 people with smoldering multiple myeloma, a pre-cancer condition. The main goal is to see if the combination is safe and tolerable, and to check if it boosts the immune system to fight the disease. Researchers also monitor changes in myeloma-related proteins in the blood and urine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University Hospital of Cleveland- Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.